摘要
目的检测不同类型冠状动脉粥样硬化性心脏病（CHD）患者血清超敏C反应蛋白（hs—CRP）水平，探讨其对CHD的临床应用价值。方法选择不同类型CHD患者共834例，其中无症状性CHD（LCHD）患者173例，稳定型心绞痛（SAP）患者241例，不稳定型心绞痛（UAP）患者265例，急性心肌梗死（AMI）患者155例；对照组122例。采用微粒子增强透射免疫分析法测定血清hs—CRP水平。结果LCHD组与对照组相比，hs—CRP水平及异常发生率差异无统计学意义（P〉0．05）；其他类型组hs—CRP水平及异常发生率均高于对照组，差异具有统计学意义（P〈0．05），并且hs—CRP水平呈现AMI组〉UAP组〉SAP组趋势（P〈0．05）。结论不同类型CHD患者血清hs—CRP水平存在差异，hs—CRP可能参与了CHD的发生发展。
Objective To detect levels of serum hs-CRP in different classification coronary heart disease （CHD） patients and explore its＇ clinical values. Methods The serum level of hs-CRP were detected by particle enhanced immunoturbidimetric assay in 834 CHD patients （173 cases of LCHD, 241 cases of SAP, 265 cases of UAP, 155 cases of AMI） and 122 control individual. Results There was not significant difference in abnormal occurrence rates and level of serum hs-CRP between LCHD group and control group. Abnormal occurrence rates and level of serum hs-CRP in other groups of CHD were significantly higher than that in control group. The trend of abnormal occurrence rates and level of serum hs-CRP in other groups of CHD was AMI〉UAP〉SAP （P〈0.05）. Conclusion There are difference of serum level of hs-CRP among different classification CHD patients. Hs-CRP may participate in the generation and development of CHD.
出处
《中国心血管病研究》
CAS
2013年第2期95-96,共2页
Chinese Journal of Cardiovascular Research
